Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
International Ophthalmology
Erschienen in: International Ophthalmology 6/2014

01.12.2014 | Review

The role and treatment of inflammation in dry eye disease

verfasst von: Ayse Yagci, Canan Gurdal

Erschienen in: International Ophthalmology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Dry eye syndrome is a common ocular surface problem, affects 10–30 % of the population, especially in those who are older than 40 years. As a consequence of the demographic pressure created by the aging population, its prevalence is expected to increase as well as its burden on ophthalmologic practices. Thus, understanding the complex underlying mechanisms and development of thoughtful, effective strategies that involve these mechanisms are critical. Many factors causing ocular surface damage and inflammation have been shown to contribute to the etiopathogenesis. Increased osmolarity induces ocular surface inflammation leading to disruption of both the quality and quantity of tears. Pathologic tear function and the ocular surface inflammation affects the neural arcade and increases apoptosis in the ocular surface cells thus creating a viscous cycle for dry eye by causing unstable and hyperosmolar tears. Thus, the treatment objective is to prevent severe dry eye complications via preventing inflammation and apoptosis of the ocular surface cells. The ultimate target is a normalized ocular surface, increased tear stability, and decreased osmolarity of the tear film. In the light of current literature, this review aims to elucidate the role of inflammation as the main etiological factor in dry eye disease and discuss current therapeutic approaches to overcome it.
Literatur
1.
The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5(2):75–92
2.
Miljanovic B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143(3):409–415PubMedCentralPubMedCrossRef
3.
4.
Barabino S, Chen Y, Chauhan S, Dana R (2012) Ocular surface immunity: homeostastic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 31:271–285PubMedCentralPubMedCrossRef
5.
Alves M, Fonseca EC, Alves MF et al (2013) Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf 11(3):181–192PubMedCrossRef
6.
Pflugfelder SC, Corrales RM, de Paiva CS (2013) T helper cytokines in dry eye disease. Exp Eye Res 117:118–125PubMedCrossRef
7.
Stern ME, SchaumburgCS Dana R, Calonge M, Niederkorn JY, Pflugfelder SC (2010) Authoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol 3:425–442PubMedCentralPubMedCrossRef
8.
Baudouin C, Aragona P, Messmer E et al (2013) Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of OCEAN group meeting. Ocul Surf 11(4):246–258PubMedCrossRef
9.
Stern ME, Schaumburg CS, Pflugfelder SC (2013) Dry eye as a mucosal autoimmune disease. Int Rev Ophthalmol 32:19–41
10.
Stern ME, Gao J, Siemasko KF et al (2004) The role of lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 78:409–416PubMedCrossRef
11.
Cursiefe C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 92:50–57CrossRef
12.
13.
Pflugfelder SC, De Paiva CS, Villarreal AL et al (2008) Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 27(1):64–69PubMedCrossRef
14.
El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R (2009) Characterization of effector T cells in dry eye disease. Investig Ophthalmol Vis Sci 50(8):3802–3807CrossRef
15.
Shen L, Barabino S, Taylor AW, Dana MR (2007) Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol 125:908–915PubMedCrossRef
16.
Hamrah P, Liu Y, Zhang Q, Dana M (2003) Alteration in corneal stromal dentritic cell phenotype and distribution in inflammation. Arch ophtalmol 121:1132–1140CrossRef
17.
Li DQ, Chen Z, Song XJ et al (2004) Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Investig Ophthalmol Vis Sci 45(12):4302–4311CrossRef
18.
19.
Enríquez-de-Salamanca A, Castellanos E, Stern ME et al (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16:862–873PubMedCentralPubMed
20.
21.
Yeh S, Song XJ, Farley W et al (2003) Apoptosis of ocular surface cells in experimentally induced dry eye. Investig Ophthalmol Vis Sci 44(1):124–129CrossRef
22.
Perry HD (2008) Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 14(3):79–87
23.
Gao J, Morgan G, Tieu D et al (2004) ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res 78:823–835PubMedCrossRef
24.
Chauhan SK, El Annan J, Ecoiffier T et al (2009) Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 182:1247–1252PubMedCentralPubMedCrossRef
25.
Dohlman TH, Chauhan SK, Kodati S et al (2013) The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. Investig Ophthalmol Vis Sci 54:4081–4091CrossRef
26.
de Paiva CS, Villarreal AL, Corrales RM et al (2007) Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-{gamma}. Investig Ophthalmol Vis Sci 48:2553–2560CrossRef
27.
Corrales RM, Stern ME, De Paiva CS et al (2006) Desiccating stress stimulates expression of matrix metalloproteinases by corneal epithelium. Investig Ophthalmol Vis Sci 47(8):3293–3302CrossRef
28.
29.
de Paiva CS, Chotikavanich S, Pangelinan SB et al (2009) IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2(3):243–253PubMedCentralPubMedCrossRef
30.
Dastjerdi MH, Dana R (2009) Corneal nerve alterations in dry eye–associated ocular surface disease. Int Ophthalmol Clin 49(1):11–20PubMedCrossRef
31.
Villani E, Magnani F, Viola F et al (2013) In vivo confocal evaluation of the ocular surface morpho-functional unit in dry eye. Optom Vis Sci 90:576–586PubMedCrossRef
32.
Labbe´ A, Alalwani H, Van Went C et al (2012) The relationship between sub-basal nerve morphology and corneal sensation in ocular surface disease. Investig Ophthalmol Vis Sci 53:4926–4931CrossRef
33.
Eldridge DC, Sullivan BD, Berg MD, Durrie DS, Lemp MA (2010) Longitudinal variability of tear film osmolarity in normal and dry eye patients. Investig Ophthalmol Vis Sci 51(5):3379–3381
34.
Goto T, Zheng X, Okamoto S, Ohashi Y (2004) Tear film stability analysis system: introducing a new application for videokerathography. Cornea 23(8 suppl):65–70CrossRef
35.
Sambursky R, Davitt WF 3rd, Latkany R et al (2013) Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immünoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 131(1):24–28PubMedCrossRef
36.
Wei Y, Gadaria-Rathod N, Epstein SP et al (2013) Tear cytokine profile as a non-invasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Investig Ophthalmol Vis Sci 7:8327–8336CrossRef
37.
Epstein SP, Gadaria-Rathod N, Wei Y et al (2013) HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease. Exp Eye Res 111:95–104PubMedCentralPubMedCrossRef
38.
Villani E, Galimberti D, Del Papa N et al (2013) Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study. Innate Immün 19(4):42
39.
Kanellopoulos AJ, Asimellis G (2014) In vivo 3-dimensional corneal epithelial thickness mapping as an indicator of dry eye: preliminary clinical assessment. Am J Ophthalmol 157:63–68PubMedCrossRef
40.
Villani E, Mantelli F, Nucci P (2013) In-vivo confocal microscopy of the ocular surface: ocular allergy and dry eye. Curr Opi Allergy Clin Immunol 13:569–576CrossRef
41.
Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R (2007) The cornea in Sjogren’s syndrome: an in vivo confocal study. Investig Ophthalmol Vis Sci 48:2017–2022CrossRef
42.
Mantopoulos D, Cruzat A, Hamrah P (2010) In vivo imaging of corneal inflammation: new tools for clinical practice and research. Semin Ophthalmol 25(5–6):178–185PubMedCentralPubMedCrossRef
43.
Villani E, Baudouin C, Efron N et al (2014) In vivo confocal microscopy of the ocular surface: from bench to bedside. Cuurent Eye Res 39(3):213–231CrossRef
44.
Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf 5(2):163–178
45.
Behrens A, Doyle JJ, Stern L, Dysfunctional tear syndrome study group et al (2006) Dysfunctional tear syndrome a Delphi approach to treatment recommendations. Cornea 25:900–907PubMedCrossRef
46.
Asbell PA (2006) Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin 22:2149–2157PubMedCrossRef
47.
Iskeleli G, Kizilkaya M, Arslan OS et al (2002) The effect of artificial tears on corneal surface regularity in patients with Sjögren syndrome. Ophthalmologica 216:118–122PubMedCrossRef
48.
Huang FC, Tseng SH, Shih MH et al (2002) Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 109:1934–1940PubMedCrossRef
49.
Kaercher T, Buchholz P, Kimmich F (2009) Treatment of patients with keratoconjunctivitis sicca with Optive™: results of a multicenter, open-label observational study in Germany. Clin Ophthalmol 3:33–39PubMedCentralPubMed
50.
Guillon M, Maissa C, Ho S (2010) Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage. Contact Lens Anterior Eye 33(2):93–99PubMedCrossRef
51.
Gomes JA, Amankwah R, Powell-Richards A et al (2004) Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol 88:821–825PubMedCentralPubMedCrossRef
52.
Vehige JG, Simmons PA, Anger C et al (2003) Cytoprotective properties of carboxymethyl cellulose (CMC) when used prior to wearing contact lenses treated with cationic disinfecting agents. Eye Contact Lens 29:177–180PubMedCrossRef
53.
Lee JH, Ahn HS, Kim EK et al (2011) Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 30:175–179PubMedCrossRef
54.
Chen W, Zhang X, Li J et al (2013) Efficacy of osmoprotectants on prevention and treatment of murine dry eye. Investig Ophthalmol Vis Sci 54(9):6287–6297CrossRef
55.
Tong L, Petznick A, Lee SY, Tan J (2012) Choice of artificial tear formulation for patients with dry eye: Where do we start? Cornea 31(Supp 1):32–36CrossRef
56.
Corrales RM, Luo L, Chang EY et al (2008) Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 27:574–579PubMedCrossRef
57.
Baudouin C, Cochener B, Pisella PJ et al (2012) Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol 22(5):751–761PubMed
58.
59.
de la Maza Sainz, Serra SM, Simon Castellvi C, Kabbani O (2000) Nonpreserved topical steroids and punctal occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol 75:751–756
60.
Dogru M, Tsubota K (2011) Pharmocotherapy of dry eye. Expert opin Pharmacother 12(3):325–334PubMedCrossRef
61.
Pflugfelder SC, Maskin SL, Anderson B et al (2004) A randomized, double masked, placebo-controlled, multicenter comparison of loteprednoletabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138:444–457PubMedCrossRef
62.
Gündüz K, Özdemir Ö (1994) Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol 72:438–442CrossRef
63.
Ben Ezra D, Matamoros N, Cohen E (1988) Treatment of severe vernal keratoconjunctivitis with cyclosporine A eye drops. Transplant Proc 20(2 Suppl 2):644–649
64.
Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 107:967–974PubMedCrossRef
65.
Sall K, Stevenson OD, Mundorf TK et al (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology 107:631–639PubMedCrossRef
66.
Donnenfeld E, Pflugfelder SC (2009) Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 54(3):321–338PubMedCrossRef
67.
Utine CA, Stern M, Akpek EK (2010) Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immünol Inflamm 18(5):352–361PubMedCrossRef
68.
Baudouin C, Brignole F, Pisella PJ et al (2002) Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol 506:761–769PubMedCrossRef
69.
Kunert KS, Tisdale AS, Stern ME et al (2011) Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 118:1489–1496CrossRef
70.
Turner K, Pflugfelder SC, Ji Z et al (2000) Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporin ophthalmic emulsion. Cornea 19:492–496PubMedCrossRef
71.
Gürdal C, Genç I, Saraç O et al (2010) Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res 35(9):771–777PubMedCrossRef
72.
Kunert KS, Tisdale AS, Gipson IK (2002) Goblet cell numbers and epithelial proliferation in the conjunctiva of dry eye syndrome treated with cyclosporin. Arch Ophthalmol 120:330–337PubMedCrossRef
73.
Agarwal R, Jain AM, Saxena N et al (2013) Effect of topical cyclosporine (0.05 %) on conjunctival impression cytology in dry eye. J Evol Med Dental Sci 2(24):4277–4281CrossRef
74.
Sahli E, Hosxal BM, Zilelioglu G et al (2010) The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea 29:1412–1416PubMedCrossRef
75.
Brignole F, Pisella PJ, De Saint Jean M et al (2001) Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Investig Ophthalmol Vis Sci 42:90–95
76.
77.
Prabhasawat P, Tesavibul N, Mahawong W (2012) A randomized double-masked study of 0.05 % cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 31:1386–1393PubMedCrossRef
78.
Perry HD, Carnevale SD, Donnenfeld ED et al (2006) Efficacy of commercially available topical cyclosporine A 0.05 % in the treatment of meibomian gland dysfunction. Cornea 25:171–175PubMedCrossRef
79.
Small DS, Acheampong A, Reis B et al (2002) Blood concentrations of cyclosporine a during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 18:411–418PubMedCrossRef
80.
Perry HD, Donnenfeld ED (2004) Topical 0.05 % cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5(10):2099–2107PubMedCrossRef
81.
Perry HD, Solomon R, Donnenfeld ED et al (2008) Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 126(8):1046–1050PubMedCrossRef
82.
Dastjerdi MH, Hamrah P, Dana R (2009) High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28(10):1091–1096PubMedCentralPubMedCrossRef
83.
Mah F, Milner M, Yiu S et al (2012) PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05 % for dry eye: a retrospective review. Clin Ophthalmol 6:1971–1976PubMedCentralPubMedCrossRef
84.
Rao SN (2010) Topical cyclosporine 0.05 % for the prevention of dry eye disease progression. J Ocul Pharmacol Ther 26(2):157–164PubMedCrossRef
85.
Cross WD, Lay LF Jr, Walt JG et al (2002) Clinical and economic implications of topical cyclosporin A for the treatment of dry eye. Manag Care Interface 15(9):44–49PubMed
86.
Brown MM, Brown GC, Brown HC et al (2009) Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 127(2):146–152PubMedCrossRef
87.
Shine WE, McCulley JP, Pandya AG (2003) Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 76:417–420PubMedCrossRef
88.
Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265PubMedCrossRef
89.
Krakauer T, Buckley M (2003) Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 47:3630–3633PubMedCentralPubMedCrossRef
90.
Solomon A, Rosenblatt M, Li DQ et al (2000) Doxycycline inhibition of interleukin-1 in the corneal epithelium. Investig Ophthalmol Vis Sci 41:2544–2557
91.
Maatta M, Kari O, Tervahartiala T et al (2006) Tear fluid levels of MMP-8 are elevated in ocular rosacea: treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 244:957–962PubMedCrossRef
92.
Geerling G, Tauber J, Baudouin C et al (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investig Ophthalmol Vis Sci 52(4):2050–2064CrossRef
93.
James MJ, Gibson RA, Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71(1 Suppl):343–348
94.
Barabino S, Rolando M, Camicione P et al (2003) Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 22:97–101PubMedCrossRef
95.
Kojima T, Ishida R, Dogru M et al (2005) The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139:242–246PubMedCrossRef
96.
Versura P, Profazio V, Buzzi M et al (2013) Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 32(4):412–418PubMedCrossRef
97.
Tanaka H, Fukuda K, Ishida W et al (2013) Rebamipide increases barrier function and attenuates TNFα-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br J Ophthalmol 97(7):912–916PubMedCrossRef
98.
Kimura K, Morita Y, Orita T et al (2013) Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide. Investig Ophthalmol Vis Sci 54(4):2572–2760CrossRef
99.
Ohguchi T, Kojima T, Ibrahim OM et al (2013) The effects of 2 % rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Investig Ophthalmol Vis Sci 54(12):7793–7802CrossRef
100.
Ji YW, Byun YJ, Choi W et al (2013) Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye. Investig Ophthalmol Vis Sci 54(12):7557–7566CrossRef
101.
Huet E, Vallée B, Delbé J et al (2011) EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Am J Pathol 179(5):1278–1286PubMedCentralPubMedCrossRef
Metadaten
Titel
The role and treatment of inflammation in dry eye disease
verfasst von
Ayse Yagci
Canan Gurdal
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2014
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-014-9969-x

Weitere Artikel der Ausgabe 6/2014

International Ophthalmology 6/2014 Zur Ausgabe

Case Report

Acute and chronic Staphylococcus epidermidis post-operative endophthalmitis: The importance of biofilm production

Erratum

Erratum to: Unilateral lacrimal fistula in a patient with uterus didelphys and renal agenesis

Original Paper

The expression of vascular endothelial growth factor in pterygium tissue of atopic patients

Original Paper

Clinical Profile of Uveitis-Related Ocular Hypertension

Original Paper

A novel duplication in the PAX6 gene in a North Indian family with aniridia

Original Paper

The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Ophthalmika in der Schwangerschaft

08.03.2024 | Vitrektomie | Originalien

Operative Therapie und Keimnachweis bei endogener Endophthalmitis
Datenauswertung aus 5 Augenkliniken

04.03.2024 | Vitrektomie | Leitthema

Bakterielle endogene Endophthalmitis
Erregerspektrum und medikamentöse Therapie

27.02.2024 | Erkrankungen der Hornhaut | CME

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen